StartUp Health community member Alamar Biosciences is focused on enabling the earliest detection of diseases through a high sensitivity multiplex platform for protein biomarker analysis. The company launched the brain-specific assays in 2025, which detect brain-derived proteins in blood, a breakthrough in early neurological disease detection. Their multiplex CNS panel allows for analysis of various protein biomarkers, including nerve regeneration and inflammation. Alamar aims to expand into clinical applications and is seeking partners to help scale its impact on early disease detection.

🔬 Early Disease Detection: Alamar’s mission is to enable the earliest possible disease detection through their multiplex platform for protein biomarker analysis.

🧠 Breakthrough PTA 217 Assays: The launch of brain-specific PTA 217 assays allows for the detection of brain-derived PAL proteins in blood, improving early diagnosis of neurological diseases like Alzheimer's.

🧪 Multiplex CNS Panel: Alamar’s panel enables comprehensive analysis of various protein biomarkers related to nerve regeneration and inflammation, broadening the scope of early disease detection.

🤝 Collaborative Partnerships: Looking ahead to 2026, Alamar is focused on collaborating with clinical partners to develop lab tests and IBD assays, enhancing its translational and clinical applications.

🌍 Health Innovation Network: Being part of the Alzheimer’s Moonshot Community connects Alamar with like-minded innovators dedicated to transforming health outcomes.